Jeremy Duffield - Feb 21, 2024 Form 4 Insider Report for Prime Medicine, Inc. (PRME)

Role
Chief Scientific Officer
Signature
/s/ Karen Brown, attorney-in-fact
Stock symbol
PRME
Transactions as of
Feb 21, 2024
Transactions value $
$0
Form type
4
Date filed
2/23/2024, 05:03 PM
Previous filing
Apr 4, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRME Stock Option (right to buy) Award $0 +181K $0.00 181K Feb 21, 2024 Common Stock 181K $8.49 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 21, 2024, subject to the Reporting Person's continued service on each such vesting date.